entecavir

(redirected from Baraclude)
Also found in: Medical.
Related to Baraclude: hepatitis B
Translations

entecavir

n entecavir m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
In 2018, double digit growth for prioritized brands Opdivo, which grew by $443 million, Eliquis, which grew by $342 million, Yervoy, which grew by $115 million, as well as Orencia, helped to offset significant declines in established brands Baraclude, Reyataz, Sustiva, and Hepatitis C franchises (for which revenues have all but disappeared), representing a total of $1.5 billion in lost revenue as compared to 2017.
Hoffmann-La Roche Ltd., Basel, Switzerland) 180 [micro]g once weekly for 48 weeks and sequential treatment groups (ETV; Baraclude, Bristol-Myers Squibb, New York, USA) 0.5 mg once daily for 4 weeks followed by a combination of ETV and Pegasys (for 8 weeks), followed by Pegasys alone (for 40 weeks).
M2 PHARMA-March 28, 2018-Breckenridge Pharmaceutical wins final US FDA approval for Entecavir tablets (Baraclude) ANDA for hepatitis B infection
M2 EQUITYBITES-March 28, 2018-Breckenridge Pharmaceutical wins final US FDA approval for Entecavir tablets (Baraclude) ANDA for hepatitis B infection
A dose of 0.5mg entecavir (Baraclude; Bristol-Myers Squibb, New York, USA) was administered daily even after the introduction of add-on PEG-IFNa-2a treatment.
Globally, the hepatitis B therapeutics market is served moderately well by the available products, of which Baraclude and Viread are the most frequently prescribed.
Entecavir is a generic version of Baraclude tablets (0.5 mg and 1 mg) from Bristol-Myers Squibb.
* Entecavir (Baraclude): A pill taken once a day for one year or longer.
Loss of the hepatitis B e antigen (HBeAg) and hepatitis B viral (HBV) DNA levels below 200 IU / mL after 48 weeks of therapy occurred in 18% of patients randomized to entecavir (Baraclude) and pegylated interferon alfa-2a (Pegasys), vs.
In 2011, only two blockbusters existed in the market - Baraclude for treating hepatitis B and Incivek for treating hepatitis C.
CS (OS) 534/2010], a suit filed for the permanent injunction restraining the defendant from infringing the patent IN213457 in respect of the drug "Baraclude", the Delhi High Court refused to grant the interim injunction to Bristol-Myers Squibb (BMS) on the ground that patent in suit is a product by process patent and not a pure product patent.